Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 2 Multivariable Cox analysis for survival outcomes between group A and B

From: Lymphocyte recovery from radiation-induced lymphopenia in locally advanced esophageal squamous cell carcinoma: correlations with prognosis and lymphocyte-related organs

 

OS

PFS

LRFS

DMFS

HR (95% Cl)

p

HR (95% Cl)

p

HR (95% Cl)

p

HR (95% Cl)

p

Tumor stage*

 

0.371

–

–

 

0.308

 

0.375

 II

0.66 (0.27–1.64)

   

0.63 (0.25–1.54)

 

0.68 (0.30–1.58)

 

 III + IV

Ref

   

Ref

 

Ref

 

Groups

 

0.002

 

 < 0.001

 

0.001

 

 < 0.001

 Group A

2.80 (1.47–5.34)

 

3.67 (2.09–6.46)

 

2.82 (1.51–5.26)

 

3.65 (1.96–6.78)

 

 Group B

Ref

 

Ref

 

Ref

 

Ref

 
  1. ALC: absolute lymphocyte count; CI, confidence interval; DMFS, distant metastasis-free survival; ECOG-PS: Eastern Cooperative Oncology Group performance status; HR: hazard ratio; LRFS, local recurrence-free survival; LRI, lymphocyte recovery index; OS, overall survival; PF: fluorouracil (5-FU) with cisplatin (DDP); PFS, progression-free survival; TC: PTX with carboplatin (CBP); TF: 5-FU with paclitaxel (PTX); TP: PTX with DDP
  2. *According to AJCC 6th. Group A included patients with G4 ALC nadir during dCCRT and LRI < 60% (N = 27) and group B with G4 ALC nadir during dCCRT and LRI ≥ 60% (N = 42)
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us